PharmiWeb.com - Global Pharma News & Resources
PharmiWeb Today Story
Ottimo Pharma Raises over $140 Million in Series A Financing
  • Financing led by OrbiMed, Avoro Capital, and Samsara BioCapital, with additional investment from founding investor Medicxi
  • Strengthens its leadership team with the appointments of industry veterans Rick Anderson as SVP Finance, Spencer Fisk as Chief Technical and Quality Officer, and Ling Zeng as General Counsel and EVP of Execution
  • IND-enabling studies underway for first-in-class PD1/VEGFR2 bifunctional antibody

[19 December 2024]: [London, UK/ Boston, US]: Ottimo Pharma (“Ottimo”), a private biotech company pioneering bifunctional medicines to extend the lives of people living with cancer, today announces the completion of a Series A financing round of over $140 million. The financing will accelerate the lead asset, Jankistomig, a first-in-class PD1/VEGFR2 bifunctional antibody for multiple solid tumor indications, in both IV and SC forms as well as a pipeline of follow-on bifunctional assets.

The round was led by OrbiMed, Avoro Capital, Samsara BioCapital, and included blue chip investors RTW Investments, Decheng Capital, Janus Henderson Investors, J.P. Morgan Life Sciences Private Capital, Invus, and founding investor Medicxi. In connection with the financing Peter Thompson (OrbiMed), Mark Chin (Avoro Capital), and Srini Akkaraju (Samsara BioCapital) will join the Board of Directors.

Simultaneously, Ottimo has expanded its management team under the leadership of David Epstein, Chair and Chief Executive Officer. The Company announces the appointment of Rick Anderson as SVP Finance, Spencer Fisk as Chief Technical and Quality Officer, and Ling Zeng as General Counsel an…

Read More...
Ottimo Pharma Raises over $140 Million in Series A Financing

Articles